Technologies Available for Licensing
COMPOSITIONS CONTAINING FULL-LENGTH L1R NUCLEIC ACID AND ENDOPLASMIC RETICULUM TARGETING SEQUENCE, AND METHODS OF USE
The invention described here encompasses DNA and protein vaccines against poxviruses, and relevant immunogenic compositions, comprising at a minimum a nucleic acid encoding a modified full-length poxvirus L1R gene or its ortholog. The L1R gene is modified so that an endoplasmic reticulum-targeting sequence is operably linked on the 5' end. Preferably the nucleic acid sequences for other poxviruses antigens are also included, such as A33R, B5R and/or A27L. These vaccines and compositions provide improved neutralizing antibody response elicited by molecular poxvirus vaccines, over known vaccines using unmodified L1R.
More Detail:Visit USPTO.GOV
Inventor(s):HOOPER, ET AL